Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VGX-3100 for HPV-related Anal HSIL
NCT03499795Phase 2Completed
- Sponsor
- Inovio Pharmaceuticals, Inc.
- Start
- May 2018
- Primary completion
- Jun 2020
- Modality
- Prophylactic Vaccines, DNA Vaccines, Cancer Vaccines
- Countries
- 2
01
Overview
A Phase 2 trial of bizalimogene ralaplasmid in anal squamous intraepithelial lesion (ASIL), perianal squamous intraepithelial lesion (AIN), sponsored by Inovio Pharmaceuticals, Inc.. Started May 2018; status: completed.
02
Drugs
bizalimogene ralaplasmid
03
Conditions
anal squamous intraepithelial lesion (ASIL)perianal squamous intraepithelial lesion (AIN)
Beyond the preview
Go deeper on NCT03499795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03499795.